Heat shock protein vaccines against glioblastoma: from bench to bedside

Immunotherapeutic Advancements for Glioblastoma

(2015) Leonel Ampie et al.   Frontiers in Oncology

Reliability of HSP70 (HSPA) expression as a prognostic marker in glioma

(2014) Glenda Maria Beaman et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Is there a role for vaccine-based therapy in recurrent glioblastoma?

(2014) M. C. Chamberlain   NEURO-ONCOLOGY

Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccination for Recurrent Glioblastoma: A Phase II, Single Arm Trial

(2014) O. Bloch et al.   NEURO-ONCOLOGY

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heat-shock protein peptide complex–96 vaccination for recurrent glioblastoma: a phase II, single-arm trial

(2013) Orin Bloch et al.   NEURO-ONCOLOGY

Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein

(2012) C. A. Crane et al.   CLINICAL CANCER RESEARCH

Heat shock protein–peptide complex in the treatment of glioblastoma

(2011) Alfred P See et al.   Expert Review of Vaccines

Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy

(2010) Robert M. Prins et al.   CLINICAL CANCER RESEARCH

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma

(2010) S. Kunwar et al.   NEURO-ONCOLOGY

Glioblastoma-Derived Mechanisms of Systemic Immunosuppression

(2009) Allen Waziri   NEUROSURGERY CLINICS OF NORTH AMERICA

Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group

(2008) Alessandro Testori et al.   JOURNAL OF CLINICAL ONCOLOGY

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

(2008) Christopher Wood et al.   LANCET